MPM BioImpact’s Relmada Therapeutics RLMD Stock Holding History

MPM BioImpact’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-138,000	Closed	-$3.73M	–	40
2022 Q1	$3.73M	Buy	+138,000	New	+$2.85M	1%	29

Other funds holding RLMD

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

MPM BioImpact's RLMD Position: Q2 2022 in Review

MPM BioImpact sold out of Relmada Therapeutics (RLMD) in Q2 2022, closing a stake of 138,000 shares — an estimated $3.73M sold.

MPM BioImpact first reported a position in RLMD in Q1 2022 and held it in 1 quarter. The position peaked at $3.73M in Q1 2022. 113 funds tracked by Wall St. Rank hold RLMD as of Q2 2022.

MPM BioImpact reported no remaining Relmada Therapeutics position as of Q2 2022 after selling out during the quarter.
MPM BioImpact sold 138,000 Relmada Therapeutics shares in Q2 2022, an estimated $3.73M.
MPM BioImpact first reported a position in Relmada Therapeutics in Q1 2022 and held it in 1 quarter.
MPM BioImpact's Relmada Therapeutics position peaked at $3.73M in Q1 2022.
113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2022.

Based on MPM BioImpact's 13F filing for Q2 2022, filed 11 Aug 2022.